Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial.
In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...